Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Imaging with 18F-FDG PET is increasingly accepted as a valuable tool for lymphoma management. A recent shift in the use of PET and PET/CT in medical practice has become evident. We selected aggressive lymphomas as a platform for the discussion of these imaging modalities in oncology patients and the resulting management questions.


METHODS
On the basis of our clinical experience and a review of the literature, we evaluated the emerging role of 18F-FDG PET in staging, response assessment, risk stratification, and tailored therapy. We explored the biologic meaning of true-positive or true-negative PET results in assessing tumor killing and the implications for risk-adapted therapy of lymphoma.


RESULTS
PET/CT improves the accuracy of staging and response assessment over that of conventional anatomic imaging. The strong prognostic value of PET for aggressive lymphomas is established, whether the imaging is performed at the end of therapy or after only a few cycles of chemotherapy. How to modify therapy on the basis of PET results is not yet established, although it is clear that high-risk patient subsets can be reliably identified.


CONCLUSIONS
PET/CT improves the accuracy of staging and response assessment over that of CT alone. A negative midtreatment PET result does not indicate the absence of a viable tumor or that therapy can be abbreviated or reduced in intensity. Similarly, a positive PET result does not necessarily indicate a viable tumor or that extending or intensifying treatment will benefit the patient. In assessing response, it is possible that prognosis rests not only on whether the PET result is positive or negative but also on the intensity of the signal. Although the prognostic value of PET for lymphoma is now clear, how to tailor therapy accordingly is a separate matter that requires further investigation.
Kasamon
Yvette L
YL
Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Jones
Richard J
RJ
Wahl
Richard L
RL
D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000628:therapy*; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D018511:Systems Integration; D013673:Technology Assessment, Biomedical; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome; D051598:Whole Body Imaging / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18